Pfizer CEO Albert Bourla buys $1 million of PFE shares in first open-market purchase
AI Market Summary
Pfizer CEO Albert Bourla's first open-market buy ($1m at $26.34) alongside recent board purchases signals insider confidence after a quarterly beat (EPS $0.77 vs $0.68; revenue $15.03bn vs $14.40bn) driven by Eliquis demand. The combination of insider buying and better-than-expected results can improve near-term sentiment toward PFE, reinforcing perceptions of operational stabilization post-COVID vaccine demand decline.
Impact level
● Medium
Affected assets
NCSKPFE2USD/USDT+0.22%
AI Insight · NCSKPFE2USD/USDTAI Insight
▲ Bullish
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Pfizer CEO Albert Bourla made his first open-market purchase of the company’s stock, buying 38,000 shares at $26.34 each for about $1 million. Board members Ronald Blaylock and Mortimer Buckley also bought a combined $2 million of PFE shares earlier in August. Pfizer’s latest quarterly results topped Wall Street expectations, with revenue of $15.03 billion and earnings per share of $0.77. PFE shares are up 14% this year, in line with the S&P 500’s gain.
